Look inside
Sixteen pages, seven original charts
Every chart and the map were built for this report from the sources named in each caption. Nothing here is stock.
Page 1 of 16
Jump to a page
Thailand treats the region. It does not, for the most part, make what it treats the region with. As the BCG framework reaches the end of its cycle and a new Medical Hub decade begins, can healthcare demand finally pull an industry behind it?
Siam Bioscience, the Government Pharmaceutical Organization, and the Chulalongkorn, Mahidol and Siriraj research base. Almost everything Thailand originates starts within an hour of here.
Thailand has roughly 151 GMP-certified pharmaceutical production facilities. Around twelve of them can make an active pharmaceutical ingredient. Every square below is one site.
of Thai GMP sites can make an active ingredient. The rest formulate what India and China supply. The pandemic showed what that exposure means when borders close.
They differ in maturity, in capital intensity and in who owns the upside. Treating them as one national story is how most coverage of Thailand goes wrong.
Thai biologics capacity was built ahead of Thai and regional demand. The gap has to be filled by contract work or it is stranded capital. The figure predates the AstraZeneca programme and is flagged for confirmation in the report.
The health system was built first. The industrial proof points arrived late, in a cluster. Select a year to see what happened.
The single most consequential health policy decision in modern Thailand, and the demand engine everything else in this report rests on.
Every chart and the map were built for this report from the sources named in each caption. Nothing here is stock.
The report follows the same architecture as every title in the series. Select a beat to see what it covers.
Three questions. Most people who work in this region get at least one wrong, which is roughly the point of the report.
Tell us where to send it. We use these details to understand who reads the series and to send you the next report in it.
Country reporting in our sector has a habit of reading like an investment brochure. The temptation is understandable. Every market has a genuine achievement to point at, every ministry has a strategy document, and it is far easier to describe ambition than to test it. The result is a body of coverage that tells a reader what a country hopes to be and almost nothing about what it currently is.
This series was built to do the opposite. Each report asks one question, answers it with attributed evidence, and names the constraints in a dedicated section that we do not allow to be softened. In Thailand's case that meant writing plainly that a country celebrated across Asia for its hospitals imports most of what those hospitals dispense, and that its most impressive industrial asset carries an open question about whether it is being used.
None of that is a verdict against Thailand. It is the opposite. The three proofs set out in this report are real and were hard won, and the gap between them and a functioning sector is smaller than it looks. But it will not close because someone wrote a favourable report about it. It closes when capital with a long horizon, an institution built to win trials, and a policy framework that survives an election arrive at the same time. Our job is to say so while there is still time to act on it.
My thanks to the BioSpectrum Asia editorial team, and to the researchers, regulators and company leaders across the region who answer our questions candidly. Singapore was first in this series, Taiwan second. Thailand is third. South Korea follows.